CDK7 and cancer: Critically, we reveal that the pharmacological targeting of CDK12 in combination with either the inhibitors against P-TEFb and CDK7 or inhibitors of IKKβ and ATM of the DNA damage-induced NF-κB pathway leads to a synergistic drop of cancer cell proliferation irrespective of p53.